Grafa News and Videos — Page 942

REGENXBIO (NASDAQ:RGNX) said it has completed dosing in the confirmatory study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, marking completion of its registrational development program.

Teledyne Technologies Incorporated (NYSE:TDY) announced that its Teledyne FLIR Defense unit has received a $28.8 million contract from U.S. Customs and Border Protection to support the Enhanced Mobile Surveillance Capability–Lite program.

CalciMedica (NASDAQ:CALC) reported that the U.S. Food and Drug Administration reviewed a protocol amendment and interim safety data from its Phase 2 KOURAGE trial and provided no comments, allowing dosing to continue.

Bowman (NASDAQ:BWMN) secured $11.2 million in new USDA aerial acquisition awards under the PINE Blanket Purchase Agreement.

Gilat Satellite Networks (NASDAQ:GILT) received a multi-million dollar order from a European Ministry of Defense for custom satellite communications terminals, with deliveries expected over the next 12 months.

Crown Crafts (NASDAQ:CRWS) reported fourth quarter fiscal 2026 net sales of $22.4 million compared with $23.2 million in the prior-year quarter.

Merck (NYSE:MRK) announced that the European Commission approved KEYTRUDA (pembrolizumab), in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment followed by adjuvant treatment after radical cystectomy for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.

Helus Pharma (NASDAQ:HELP) reported that its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment and is progressing as planned.

Elon Musk's SpaceX priced US$25 billion in investment-grade corporate bonds on 23 June 2026, marking one of the largest debut bond sales on record.

Absci Corp (NASDAQ:ABSI) reported positive interim Phase 1 data from the HEADLINE trial evaluating ABS-201, an investigational anti-PRLR antibody in development.